Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: An open, randomized, controlled trial

Modern Rheumatology

Volumn 24, Issue 4, 2014, Pages 561-566

  Kurasawa, Takahiko ^a,b   Nagasawa, Hayato ^a   Kishimoto, Mayumi ^c   Amano, Koichi ^a   Takeuchi, Tsutomu ^b   Kameda, Hideto ^b,d  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b Department of Surgery (Omori)   (Japan)

^c SANTEN PHARMACEUTICAL CO LTD   (Japan)

^d TOHO UNIVERSITY   (Japan)

Author keywords

Biological agents; Bucillamine; DMARD combination; Flare; Remission

Indexed keywords

BUCILLAMINE; C REACTIVE PROTEIN; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; STROMELYSIN; ANTIRHEUMATIC AGENT; CYSTEINE; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG ERUPTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; OPEN STUDY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; TERATOGENICITY; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ARTHRITIS, RHEUMATOID; DISEASE COURSE; DRUG COMBINATION; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYSTEINE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903735257     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.844886     Document Type: Article

References (25)

1. Goronzy JJ, Weyand CM. Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res Ther. 2009;11(5):249.
2. Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, et al.; for the T2T Expert Committee: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631-7.
3. Kiely PD, Deighton C, Dixey J, Ostör AJ; British Society for Rheumatology Standards, Guidelines and Audit Working Group. Biologic agents for rheumatoid arthritis-negotiating the NICE technology appraisals. Rheumatology (Oxford). 2012;51(1):24-31.
4. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelvemonth randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(1):27-35.
5. Goekoop-Ruiterman YPM, de Vries-Bouwsta JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies in early rheumatoid arthritis. A randomized trial. Ann Intern Med. 2007;146(6):406-15.
6. Buch MH, Marzo-Ortega H, Bingham SJ, Emery P. Long-term treatment of rheumatoid arthritis with tumour necrosis factor α blockade: outcome of ceasing and restarting biological. Rheumatology (Oxford). 2004;43(2):243-4.
7. Saleem B, Keen H, Goeb V, Parmar R, Nizam S, Hensor EM, et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis. 2010;69(9):1636-42.
8. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al.; RRR study investigators. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010;69(7):1286-91.
9. Sekiguchi N, Kameda H, Amano K, Takeuchi T. Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis. Mod Rheumatol. 2006;16(2):85-91.
10. Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, et al.; MTX-BUC Combination Study Group; Japanese Ministry of Health, Labour and Welfare's " Research for Establishment of Therapeutic Guidelines in Early Rheumatoid Arthritis ". Therapeutic Effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod Rheumatol. 2005;15(5):323-8.
11. Eguchi K, Kawakami A, Ida H, Nakashima M, Yamashita I, Sakai M, et al. Bucillamine inhibits T cell adhesion to human endothelial cells. J Rheumatol. 1992;19(7):1045-50.
12. Hashimoto K, Lipsky PE: Immunosuppression by the disease modifying antirheumatic drug bucillamine: Inhibition of human T lymphocyte function by bucillamine and its metabolites. J Rheumatol. 1993;20(6):953-7.
13. Hirohata S, Lipsky PE. Comparative inhibitory Effects of bucillamine and D-penicillamine on the function of human B cells and T cells. Arthritis Rheum. 1994;37(6):942-50.
14. Matsuno H, Sugiyama E, Muraguchi A, Nezuka T, Kubo T, Matsuura K, Tsuji H. Pharmacological Effects of SA96 (bucillamine) and its metabolites as immunomodulating drugs-the disulfide structure of SA-96 metabolites plays a critical role in the pharmacological action of the drug. Int J Immunopharmacol. 1998; 20(6): 295-304.
15. Aono H, Hasunuma T, Fujisawa K, Nakajima T, Yamamoto K, Mita S, Nishioka K. Direct suppression of human synovial cell proliferation in vitro by salazosulfapyridine and bucillamine. J Rheumatol. 1996; 23(1):65-70.
16. Nagashima M, Wauke K, Hirano D, Ishigami S, Aono H, Takai M, et al. Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology (Oxford). 2000;39(11):1255-62.
17. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of disease activity score (DAS) 28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis. 2007;66(3):407-9.
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.
19. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-3.
20. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al.; American College of Rheumatology; European League Against Rheumatism. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011; 63: 573-86
21. Ann Rheum Dis. 2011;70:404-13.
22. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A; Swiss Clinical Quality Management Physicians: Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Care Res. 2009;61(5):560-8.
23. van der Maas A, Kievit W, van den Bemt BJF, van den Hoogen FH, van Riel PL, den Broeder AA. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis. 2012;71(11):1849-54.
24. Iwatani M, Inoue E, Nakamura T, Nakajima A, Hara M, Tomatsu T, Kamatani N, Yamanaka H. Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. Mod Rheumatol. 2006;16(6):376-80.
25. Nakagomi D, Ikeda K, Kawashima H, Kobayashi Y, Suto A, Nakajima H. Bucillamine-induced yellow nail in Japanese patients with rheumatoid arthritis: two case reports and a review of 36 reported cases. Rheumatol Int. 2013;33(3):793-7 (Nov 17 2011 Epub ahead of print).